. Author manuscript; available in PMC: 2011 Jul 28.

Published in final edited form as: Nat Rev Endocrinol. 2010 Sep 21;6(11):619–628. doi: 10.1038/nrendo.2010.169

Table 2.

Meta-analyses of trials examining the effect of aspirin in diabetes mellitus

Reference	Trials included	Effect of aspirin on coronary heart disease events^*	Effect of aspirin on stroke^*	Comments
Baigent et al.²	BMD, PHS, PPP, WHS, TPT, HOT	NA	NA	Effect of aspirin on cardiovascular events: 0.88 (0.82–0.94)
Calvin et al.⁵²	PHS, PPP, WHS, HOT, ETDRS, JPAD, POPADAD^‡	0.86 (0.67–1.11)	0.62 (0.31–1.24)	NA
DeBerardis et al.⁵¹	PHS, PPP, WHS, ETDRS, JPAD, POPADAD^§	0.86 (0.61–1.21)	0.83 (0.60–1.14)	NA
Pignone et al.⁹	BMD, PHS, PPP, WHS, TPT, HOT, ETDRS, JPAD, POPADAD	0.91 (0.79–1.05)	0.90 (0.71–1.13)	Used additional data provided by ATT investigators
Zhang et al.⁵³	PHS, PPP, WHS, HOT, ETDRS, JPAD, POPADAD^§	0.85 (0.65–1.11)	0.83 (0.63–1.10)	Important differences in effect for men and women identified with meta-regression No evidence of publication bias

Values state the relative risk and CIs are listed in brackets.

^‡

Only included JPAD and WHS for stroke.

^§

Did not include PHS for stroke.

Abbreviations: ATT, Anti-Thrombotic Trialists; BMD, British Medical Doctors study; ETDRS, Early Treatment of Diabetic Retinopathy trial; HOT, Hypertension Optimal Treatment; JPAD, Japanese Prevention of Atherosclerosis with Aspirin in Diabetes trial; NA, not applicable; POPADAD, Prevention of Progression of Arterial Disease and Diabetes trial; PHS, Physicians Health Study; PPP, Primary Prevention Project; RR, relative risk; TPT, Thrombosis Prevention Trial; WHS, Womens Health Study.